189 related articles for article (PubMed ID: 16148729)
1. Infections associated with tumor necrosis factor-alpha antagonists.
Crum NF; Lederman ER; Wallace MR
Medicine (Baltimore); 2005 Sep; 84(5):291-302. PubMed ID: 16148729
[TBL] [Abstract][Full Text] [Related]
2. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis.
Inanc N; Direskeneli H
Rheumatol Int; 2006 Nov; 27(1):67-71. PubMed ID: 16896990
[TBL] [Abstract][Full Text] [Related]
3. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
4. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
[TBL] [Abstract][Full Text] [Related]
5. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
6. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers.
Ruyssen-Witrand A; Gossec L; Salliot C; Luc M; Duclos M; Guignard S; Dougados M
Clin Exp Rheumatol; 2007; 25(3):430-6. PubMed ID: 17631740
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
8. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Collamer AN; Battafarano DF
Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
[TBL] [Abstract][Full Text] [Related]
9. The yin and yang of tumor necrosis factor inhibitors.
Calabrese L
Cleve Clin J Med; 2006 Mar; 73(3):251-6. PubMed ID: 16548447
[TBL] [Abstract][Full Text] [Related]
10. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
Williams VL; Cohen PR
Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
[TBL] [Abstract][Full Text] [Related]
11. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
Gaudin P
Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
[No Abstract] [Full Text] [Related]
12. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database.
Béné J; Moulis G; Auffret M; Lefevre G; Coquerelle P; Coupe P; Péré P; Gautier S
Rheumatology (Oxford); 2014 Aug; 53(8):1465-9. PubMed ID: 24681837
[TBL] [Abstract][Full Text] [Related]
13. [Are there differences among anti-TNFα biological drugs?].
Valesini G
Reumatismo; 2005; 57(4 Suppl):1-2. PubMed ID: 16385348
[TBL] [Abstract][Full Text] [Related]
14. TNF-alpha antagonists: pulmonary legionellosis.
Prescrire Int; 2007 Feb; 16(87):20. PubMed ID: 17326282
[TBL] [Abstract][Full Text] [Related]
15. [TNF targetting therapy for rheumatoid arthritis].
Takeuchi T
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1787-94. PubMed ID: 17037316
[No Abstract] [Full Text] [Related]
16. [A new clinical disease entity. Tuberculosis in users of TNF-alpha inhibitors].
Trautmann M
Pharm Unserer Zeit; 2012 Jan; 41(1):79-83. PubMed ID: 22470924
[No Abstract] [Full Text] [Related]
17. [Safety of anti-TNFα biological drugs].
Trotta F; Valentini G
Reumatismo; 2005; 57(4 Suppl):34-9. PubMed ID: 16385354
[TBL] [Abstract][Full Text] [Related]
18. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
Asahina A; Ishii N; Tohma S
J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
[No Abstract] [Full Text] [Related]
19. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Finckh A; Simard JF; Gabay C; Guerne PA;
Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
[TBL] [Abstract][Full Text] [Related]
20. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
Saad AA; Symmons DP; Noyce PR; Ashcroft DM
J Rheumatol; 2008 May; 35(5):883-90. PubMed ID: 18381787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
